Mandate

Vinge advises international private equity firm Cinven on the acquisition of Envirotainer

July 12, 2018 M&A

Headquartered in Stockholm, Envirotainer designs, manufactures and leases active temperature-controlled containers used primarily for air freighting biopharma products, transporting up to two millions doses of medicine per day. Envirotainer serves c. 600 customers worldwide, including many of the blue-chip global biopharma companies.

With c. 300 employees, Envirotainer operates from regional centres in Stockholm, Frankfurt, Dallas and Singapore, with a portfolio of more than 5,500 leased containers globally. Envirotainer developed and marketed the first container with an active temperature control system in 1995 and since then has significantly invested in technology and its container fleet.

Vinge’s team consisted of partners Christina Kokko and Kristina Ekberg (M&A), Louise Brorsson Salomon and Albert Wållgren (Banking and Finance) together with associates Filip Öhrner, Samra Baytar, Karl Klackenberg, Anna Thoms, Vilhelm Rondahl and Arvid Axelryd (M&A), Linn Adelwald and Agnes Perbo (Banking and Finance), Hedvig Ekdahl, Lisa Hörnqvist and Hayaat Ibrahim (Commercial Agreements), Klara Secher (IP), Sara Strandberg and Sophia Holm (Employment), Johan Cederblad (Environment), Frida Ställborn (Real Estate) and VDR assistant Jessica Öijer.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026